Historical source coverage

2014

86 selected records with a cited source date in 2014. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2014 by record type

4 types

December 2014

8 records

Clinical trials · Pasireotide

ClinicalTrials.gov record NCT01128192

PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Bremelanotide

ClinicalTrials.gov record NCT01382719

PeptideScanner retained ClinicalTrials.gov record NCT01382719 at 2026-07-30T21:54:46.551Z. Its registry update date was 2014-12-18, and PeptideScanner's reviewed identity mapping was bremelanotide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Desmopressin

Federal Register notice 2014-28702

The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT01507389

PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Desmopressin

ClinicalTrials.gov record NCT01435083

PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Eptifibatide

ClinicalTrials.gov record NCT00317395

PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide.

Source: ClinicalTrials.gov ↗

→

November 2014

12 records

Clinical trials · Octreotide

ClinicalTrials.gov record NCT00412061

PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Gonadorelin

[Capillary isotachophoresis--a new method in drug analysis. 1. Analytic capillary isotachophoresis of the peptide drugs saralasin, gonadorelin and protirelin].

PubMed lists PMID 6412255 in Die Pharmazie as English Abstract, Journal Article, with publication-date metadata of 1983-06 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Icatibant

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pasireotide

Pasireotide for the treatment of Cushing's disease.

PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Degarelix

In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.

PubMed lists PMID 21496210 in Basic & clinical pharmacology & toxicology as Journal Article, with publication-date metadata of 2011-05-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Goserelin

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pasireotide

Pasireoride (Signifor) for Cushing's disease.

PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pasireotide

Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.

PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Bremelanotide

PubMed record PMID 14963471

PeptideScanner retained PubMed bibliographic metadata for PMID 14963471 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-02-14. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Bremelanotide

PubMed record PMID 15134289

PeptideScanner retained PubMed bibliographic metadata for PMID 15134289 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-05-12. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Elamipretide

PubMed record PMID 17151329

PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Vasopressin

ClinicalTrials.gov record NCT00379522

PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.

Source: ClinicalTrials.gov ↗

→

October 2014

7 records

Clinical trials · Dulaglutide

ClinicalTrials.gov record NCT01524770

PeptideScanner retained ClinicalTrials.gov record NCT01524770 at 2026-07-30T21:54:46.539Z. Its registry update date was 2014-10-22, and PeptideScanner's reviewed identity mapping was dulaglutide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Leuprolide

Federal Register notice 2014-23961

The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Dulaglutide

ClinicalTrials.gov record NCT01432938

PeptideScanner retained ClinicalTrials.gov record NCT01432938 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Dulaglutide

ClinicalTrials.gov record NCT01436201

PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.

Source: ClinicalTrials.gov ↗

→

September 2014

8 records

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT01166958

PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Pasireotide

Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.

PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT01270789

PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Nesiritide

ClinicalTrials.gov record NCT00573144

PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide.

Source: ClinicalTrials.gov ↗

→

August 2014

6 records

Regulatory · Leuprolide

Federal Register notice 2014-19713

The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Lanreotide

PubMed record PMID 15003204

PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT01534182

PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Regulatory · Liraglutide

Federal Register notice 2014-18304

The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

July 2014

6 records

Literature metadata · Nesiritide

The role of nesiritide in heart failure.

PubMed lists PMID 19538002 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Lanreotide

Federal Register notice 2014-17293

The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

Source: Federal Register via GovInfo ↗

→

June 2014

4 records

May 2014

12 records

Literature metadata · PEG-MGF

Microencapsulation of mechano growth factor E peptide for sustained delivery and bioactivity maintenance.

PubMed lists PMID 24768406 in International journal of pharmaceutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-04-23 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Dalbavancin

Drugs@FDA application NDA021883

The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Regulatory · Linaclotide

Federal Register notice 2014-11926

The Federal Register published notice 2014-11926, attributed to FDA and its parent HHS department, on 2014-05-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.

Source: Federal Register via GovInfo ↗

→

Regulatory · Peginesatide

Federal Register notice 2014-11523

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

Source: Federal Register via GovInfo ↗

→

Regulatory · Carfilzomib

Federal Register notice 2014-11175

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

Source: Federal Register via GovInfo ↗

→

April 2014

8 records

Clinical trials · Eptifibatide

ClinicalTrials.gov record NCT00894803

PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00211887

PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Regulatory · Icatibant

Federal Register notice 2014-07331

The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

Source: Federal Register via GovInfo ↗

→

Regulatory · Leuprolide + 1 more

Federal Register notice 2014-07330

The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→

March 2014

4 records

Regulatory · Oxytocin

Federal Register rule 2014-06131

The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT01611571

PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

February 2014

9 records

Clinical trials · Nesiritide

ClinicalTrials.gov record NCT00813202

PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT01550653

PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Cetrorelix

ClinicalTrials.gov record NCT01185704

PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix.

Source: ClinicalTrials.gov ↗

→

Regulatory · Dalbavancin

Federal Register notice 2014-02942

The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT01216072

PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Efpeglenatide

ClinicalTrials.gov record NCT01093729

PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.

Source: ClinicalTrials.gov ↗

→

January 2014

2 records

Clinical trials · Dalbavancin

ClinicalTrials.gov record NCT01339091

PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.

Source: ClinicalTrials.gov ↗

→